Research Article

Impact of Coronary Artery Disease and Percutaneous Coronary Intervention on Transcatheter Aortic Valve Implantation

Table 1

Baseline characteristics.

Whole populationCAD groupNo CAD group value CAD versus no CAD
N = 1030N = 372N = 658

Age84.3 ± 784.2 ± 784.6 ± 70.35
Male466 (45.2)196 (52.7)270 (41)<0.001
Hypertension708 (68.7)253 (68)455 (69.1)0.7
Diabetes mellitus264 (74.4)108 (29)156 (23.7)0.05
Dyslipidemia410 (39.8)175 (47)235 (35.7)<0.001
Smoking26 (2.5)6 (1.6)20 (3)0.16
BMI26.2 ± 526.2 ± 4.930.7 ± 4.70.27
Chronic respiratory disease193 (18.7)61 (16.4)132 (20.1)0.14
Atrial fibrillation394 (38.3)130 (34.9)264 (40.1)0.1
Prior stroke110 (10.7)41 (11)69 (10.5)0.78
Prior PAD69 (6.7)31 (8.3)38 (5.8)0.11
EuroScore114.2 ± 9.914.3 ± 1014 ± 100.84
STS-PROM6.35 ± 4.76.3 ± 4.75.7 ± 5.50.68
Baseline LVEF53.7 ± 11.853.2 ± 12.353.7 ± 11.50.07

Antithrombotic treatment
None247 (24)35 (9.4)212 (32.2)<0.001
Single-antiplatelet therapy245 (23.8)65 (17.5)180 (27.4)
Dual-antiplatelet therapy171 (16.6)156 (41.9)15 (2.3)
Anticoagulation therapy278 (27)49 (13.2)229 (34.8)
Antiplatelet + anticoagulation89 (8.6)67 (18)22 (3.3)

TAVI approach
Transfemoral967 (93.9)349 (93.8)618 (93.9)0.22
Transaortic54 (5.2)18 (4.8)36 (5.5)
Transapical2 (0.2)0 (0)2 (0.3)
Transsubclavian5 (0.5)4 (1.1)1 (0.2)
Transcarotid2 (0.2)1 (0.3)1 (0.2)

Valve in valve35 (3.4)14 (3.8)21 (3.2)0.62

Prosthesis type
Ballon expandable560 (54.4)217 (58.3)343 (52.1)0.05
Self-expanding470 (45.6)155 (41.7)315 (47.9)

Post-TAVI LVEF54.9 ± 10.754.7 ± 10.755.6 ± 10.90.85

CAD = coronary artery disease. BMI = body mass index. PAD = peripheral artery disease. LVEF = left ventricle ejection fraction. EuroScore = European System for Cardiac Operative Risk Evaluation. STS-PROM = Society of Thoracic Surgeons Predicted Risk of Mortality. TAVI = transcatheter aortic valve implantation. CCU = cardiac care unit. TAVI: transcatheter aortic valve implantation. CAD: coronary artery disease. PCI: percutaneous coronary intervention.